TECH — Bio-Techne price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $72.78
- YTD price return
- +23.75%
- YTD total return
- +24.29%
- Market cap
- 11.4B
- Enterprise value
- 11.6B
- Shares outstanding
- 157.1M
- 52W low
- $43.20
- 52W high
- $72.83
- From 52W high
- -0.07%
- From 52W low
- +68.47%
- 52W range
- 100%$43.20–$72.83
- Beta
- 1.28
Volume
- Rel volume
- 0.68×
- 30D volume
- 2.9M
- 30D $ vol
- 210.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$437K
Form 4 transactions by trade date, as filed; latest on file 2026-05-08.
Fundamentals
- Sales (ttm)
- 1.2B
- Sales/share
- $7.82
- EPS (ttm)
- $1.09
- FCF (ttm)
- 308.2M
- FCF/share
- $1.96
- Book value/share
- $13.79
- Net margin
- 14.00%
- ROE
- 7.94%
- ROA
- 6.52%
- Debt / equity
- 0.09×
- Current ratio
- 2.28
Growth (CAGR, ttm) · 10Y
- Sales
- +0.94%+2.40%+4.52%+9.03%
- Net income
- +120.64%-11.33%-0.53%+5.51%
- FCF
- +37.58%+12.68%+0.87%+9.39%
- Shares
- +0.80%-0.23%-0.02%+0.51%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +121.79%-10.50%+0.18%+4.97%
- Sales/share
- +0.14%+2.63%+4.54%+8.48%
- FCF/share
- +36.49%+12.94%+0.88%+8.84%
- Book value/share
- +9.30%+2.96%+5.74%+8.68%
- Dividend/share
- +0.00%+0.00%+0.00%+0.00%
- Price
- +25.11%+7.43%-10.15%+11.34%
- Total return
- +25.82%+8.00%-9.74%+11.99%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 66.6×
- P/OI (ttm)
- 47.5×
- Fwd P/E
- 31.4×
- P/S (ttm)
- 9.3×
- P/B (mrq)
- 5.3×
- P/FCF (ttm)
- 37.1×
- EV/EBITDA (fy)
- 34.3×
- EV/Sales (ttm)
- 9.4×
- FCF yield (ttm)
- 2.70%
- Dividend yield (fwd)Div yield
- 0.44%
- Dividend yield (ttm)
- 0.44%
- Dividend/share (fwd)
- $0.32
- Buyback yield (realized, 1y)
- -0.80%
- Shareholder yield (realized, 1y)
- -0.22%
- Buyback yield (cash, ttm)
- 0.36%
- Shareholder yield (cash, ttm)
- 0.80%
Vs own 10Y history
- P/E
- 63rd
- P/OI
- 43rd
- P/S
- 37th
- P/B
- 32nd
- P/FCF
- 21st
Bar = where today’s multiple sits in TECH’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +1.2%10Y CAGR +5.3%YoY −23.2%EPS (diluted)
5Y CAGR +5.9%10Y CAGR +5.2%YoY −25.0%Free cash flow
5Y CAGR −3.1%10Y CAGR +7.5%YoY +202.4%TTM: operating cash flow $337.6M, capex −$29.4M
Q1 2027: operating cash flow $73.1M, capex −$5.9M
Shares (diluted)
5Y −3.0%10Y +5.2%YoY +1.0%Dividend per share
5Y CAGR +0.0%10Y CAGR +0.0%YoY +0.0%About Bio-Techne#
Data provided bySource: Twelve DataBio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.
Minneapolis, MN·3,000 employees·Biotechnology·bio-techne.com·As of Oct 28, 2026
Recent filings#
- Nov 6Report · Quarterly report, Q1 FY2027 — revenue $299.7M (+5% y/y), net income $28.3M, EPS $0.18
- Sep 238-K · Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
- Aug 12Earnings · Earnings release — EPS $0.49 vs $0.46 est. (+6.5%); revenue $321.2M (+1% y/y) 0.1%
ETFs holding TECH#
29 of the 193 ETFs ChartRow carries live hold TECH. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 0.9% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.3% |
| XLV | Health Care Select Sector SPDR Fund | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
